FBLG Stock — FibroBiologics Inc.: Cash, EV, Pipeline

Share price

$1.43

Market cap

$9.5M

Cash

$3.5M

Enterprise value

$6.0M

Balance sheet

Cash	$3.5M
Debt	$0.0M
Net cash	$3.5M
Enterprise value	$6.0M
Basic shares	6.3M shares
Fully diluted shares	7.0M shares
Fully diluted market cap	$10.0M
Cash per share	$0.56

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading FBLG daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 11 - Mar 25	SoC	Phase 1/2	Diabetic Foot Ulcer (DFU)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

CYWC628

Phase 1 · Active Modality: fibroblast cell therapy

Indications

Diabetic foot ulcers (Phase 1)

Catalysts

— second half of 2026
— fourth quarter of 2026

Status note Topically administered allogeneic fibroblast cell-based therapy for wound healing. 12-week Phase 1/2 trial in Australia (sponsored by FibroBiologics Australia Pty Ltd) began screening/enrolling/dosing in Q2 2026; enrollment slower than anticipated.

CYPS317

Preclinical · Active Modality: fibroblast cell therapy

Indications

Psoriasis (Preclinical)

Status note Intravenously administered allogeneic fibroblast spheroid therapy for psoriasis. IND-enabling preclinical studies complete; Phase 1/2 IND application filed with FDA Dec 30, 2025.

CYMS101

Phase 1 · Active Modality: fibroblast cell therapy

Indications

Multiple sclerosis (Phase 1)

Status note Intravenously administered allogeneic fibroblast single-cell/spheroid therapy for MS. Completed Phase 1 study in Mexico.

CybroCell

Preclinical · Active Modality: fibroblast cell therapy

Indications

Degenerative disc disease (Preclinical)

Status note Intradiscal allogeneic fibroblast cell-based therapy for intervertebral disc/articular cartilage repair. FDA IND clearance received in 2018, conditional on master cell bank approval.

Per-asset detail extracted from the 10-Q filed 2026-07-31. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	SoC
Lead indication	Diabetic Foot Ulcer (DFU)
Lead phase	Phase 1/2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07096934	Phase 1/2	Recruiting	Sponsor	FibroBiologics	—	Diabetic Foot Ulcer (DFU)	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for FibroBiologics on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

FBLG — FibroBiologics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials